Yoon Hang “John” Kim, MD, MPH

Direct Integrative Care

www.directintegrativecare.com

Introduction

More than five years after SARS-CoV-2 emerged, one of the pandemic’s most consequential legacies is not the acute illness but what follows it. A substantial minority of people who contract COVID-19 do not fully return to their prior baseline. Instead, they experience a constellation of symptoms — profound fatigue, cognitive dysfunction, dysautonomia, exercise intolerance, pain, and post-exertional malaise — that can persist for months or years. This condition, formally termed post-acute sequelae of SARS-CoV-2 (PASC) and commonly known as Long COVID, is increasingly understood not as a single disease but as a post-infectious syndrome with multiple overlapping mechanisms.

The framing matters. When clinicians recognize Long COVID as a member of a broader family of post-acute infection syndromes (PAIS) — alongside ME/CFS, post-Ebola syndrome, post-Lyme disease, and post-viral sequelae described after polio, dengue, chikungunya, and Epstein-Barr virus — it changes both the clinical narrative and the research agenda.^1,2 Long COVID has, for better or worse, given the medical community a cohort large enough and vocal enough to finally force sustained attention to the biology of post-infectious illness.¹

Long COVID Within the Post-Infectious Syndrome Spectrum

Most major definitions characterize Long COVID as symptoms that persist or emerge at least four to twelve weeks after acute SARS-CoV-2 infection and cannot be explained by another diagnosis.³ The clinical picture — fatigue, brain fog, dysautonomia (including postural orthostatic tachycardia syndrome, or POTS), dyspnea, pain, and post-exertional malaise or post-exertional symptom exacerbation (PEM/PESE) — closely mirrors earlier post-viral entities, particularly myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).^3,4

Importantly, research has demonstrated that a sizable fraction of previously infected individuals now meet established ME/CFS diagnostic criteria, placing Long COVID squarely within what some investigators have called “infection-associated chronic conditions” (IACCs).^4,5 Dr. Akiko Iwasaki of Yale, one of the field’s leading immunologists, has emphasized that ME/CFS is “just one of the many branches of post-acute infection syndrome,” and that Long COVID belongs to the same biological family.⁵

Evidence for Autoimmune and Inflammatory Mechanisms

Although Long COVID is almost certainly heterogeneous, one of the most compelling and actively studied endotypes involves a dysregulated immune response with autoimmune features. The evidence can be grouped into three overlapping lines of investigation.

1. Autoantibodies in Long COVID

Multiple cohorts have documented autoantibodies — including antinuclear antibodies (ANAs), antibodies against cytokines, and antibodies targeting cell-surface and neural proteins — in people with Long COVID and in COVID-related autonomic disorders.^1,6 A 2025 systematic review in The Lancet Infectious Diseases analyzing 44 studies and 7,571 participants concluded that autoantibodies are detectable in a meaningful subset of Long COVID patients, though findings are heterogeneous and not yet sufficiently specific to serve as a validated biomarker.⁶

Perhaps the most striking recent evidence comes from Yale’s Iwasaki laboratory: when IgG antibodies were transferred from Long COVID patients into healthy mice, a subset of the animals developed symptoms consistent with the human syndrome, including heightened pain sensitivity and abnormal balance — offering some of the first experimental support for a causal, rather than merely associative, autoimmune mechanism in at least one Long COVID subtype.^7,8

2. Persistent Inflammation and Immune Dysregulation

Beyond autoantibodies, Long COVID patients frequently exhibit persistently elevated pro-inflammatory cytokines — including interferon-α, TNF-α, IL-6, and IL-17α — for months after acute infection, with levels that correlate with ongoing symptoms.⁹ This pattern is consistent with a model of chronic immune dysregulation in which the initial infection destabilizes immune homeostasis in ways that do not self-correct.^9,10

3. Proposed Drivers of Chronic Immunopathology

Current mechanistic hypotheses are not mutually exclusive and likely coexist in individual patients:

• Viral persistence and residual antigen: Biopsy, autopsy, and circulating-antigen studies have detected SARS-CoV-2 RNA and spike protein in tissues and blood months after acute infection, potentially sustaining chronic immune activation.
• Reactivation of latent viruses: Epstein-Barr virus and other herpesviruses may reactivate in the context of acute COVID-19, contributing to ongoing inflammation and symptoms.
• Molecular mimicry, bystander activation, and neoantigen formation: Cross-reactive B- and T-cell responses may target host proteins, while tissue damage may expose previously sequestered antigens.
• Autonomic and microvascular dysfunction: Endothelial injury, microclotting, and autonomic nervous system dysregulation contribute to symptoms such as POTS, exercise intolerance, and cognitive dysfunction.

Iwasaki and colleagues have consolidated these into four principal, overlapping hypotheses — persistent virus, autoimmunity, latent-virus reactivation, and unresolved tissue inflammation — emphasizing that these are not mutually exclusive and that different patients may embody different combinations.^2,11

Long COVID and New or Worsened Autoimmune Disease

Population-level data increasingly support a genuine increase in autoimmune disease risk after COVID-19. A 2025 systematic review and meta-analysis of population-based cohort studies found that SARS-CoV-2 infection was associated with a roughly one- to three-fold increased risk of at least eleven immune-mediated diseases, particularly rheumatologic conditions.¹² A separate 2025 meta-analysis pooling data on nearly 97 million individuals reached broadly similar conclusions regarding new-onset autoimmune disease following COVID-19, with risk modified by acute infection severity and vaccination status.¹³

A RECOVER Initiative study using U.S. electronic health record networks (N3C, PCORnet, PEDSnet) likewise found that SARS-CoV-2 infection was associated with new-onset autoimmune disease, with risk scaling with the severity of the acute illness.¹⁴ Earlier TriNetX-based analyses reported increased hazard ratios for conditions including cutaneous vasculitis, polyarteritis nodosa, and hypersensitivity angiitis in the year following COVID-19 diagnosis.¹⁵

Clinically, this shows up in two ways:

• De novo autoimmune diagnoses after COVID-19 — including rheumatoid arthritis–like disease, lupus-spectrum conditions, autoimmune thyroid disease, and several vasculitides.
• Flares or unmasking of pre-existing autoimmune conditions in the post-acute phase, a pattern clinicians familiar with functional and integrative medicine have observed repeatedly at the bedside.

Where the Field Is Now

Major academic centers now explicitly treat autoimmunity as one of several key endotypes within the Long COVID umbrella, alongside viral persistence, unresolved tissue damage, dysautonomia, and microvascular/endothelial pathology.^7,11 This endotype framework is driving early-phase trials of immunomodulatory and autoimmune-targeted therapies — including intravenous immunoglobulin (IVIG), B-cell depletion, FcRn inhibitors, and therapeutic apheresis — in carefully selected patient subsets.^7,16

At the same time, honest acknowledgment of the field’s limits is essential. There are not yet universally accepted diagnostic criteria, validated biomarkers, or standardized autoimmune panels specific to Long COVID.^3,6 Public-health agencies including the CDC and major academic medical centers now explicitly recognize that post-COVID multi-organ and autoimmune sequelae can last months to years and recommend longer-term clinical monitoring of affected patients.^17,18

Clinical Implications for Integrative Practice

For clinicians working at the intersection of conventional and integrative medicine, framing Long COVID as a post-infectious syndrome with immunopathic and autoimmune dimensions has several practical consequences:

• Validate the illness. Long COVID is biologically real. Dismissal — whether overt or subtle — is not just unkind; it is unscientific given the current evidence base.
• Screen for autoimmune overlap. In patients with persistent fatigue, arthralgias, rashes, Raynaud phenomenon, sicca symptoms, or new-onset dysautonomia after COVID-19, maintain a low threshold for autoimmune and rheumatologic workup.
• Consider the ME/CFS overlap. Recognize post-exertional malaise as a red flag that should shift the treatment strategy away from graded exercise and toward pacing and energy envelope management.
• Address the whole person. Sleep, nutrition, mitochondrial support, autonomic rehabilitation, judicious use of immunomodulatory strategies, and attention to latent viral reactivation all have a role in a thoughtful, individualized plan.

Conclusion

Long COVID is best understood not as a mysterious outlier but as the latest — and by far the largest — example of a phenomenon medicine has documented for more than a century: that some infections leave behind a prolonged, immunologically active aftermath. A substantial subset of Long COVID patients appear to have a significant autoimmune or immunopathic component, supported by autoantibody findings, passive transfer experiments, persistent cytokine elevations, and population-level increases in new-onset autoimmune disease after COVID-19.

Mechanisms and biomarkers are still being defined, and no single therapy will help every patient. But the scientific trajectory is clear: Long COVID has earned its place within the post-infectious syndrome family, and the lessons learned from studying it will almost certainly inform how we recognize and treat the next infection that leaves a lasting mark on at least some of those it touches.

References

1. Wilson EM. The Long COVID Puzzle: Autoimmunity, Inflammation, and Other Possible Causes. Yale Medicine. https://www.yalemedicine.org/news/the-long-covid-puzzle-autoimmunity-inflammation-and-other-possible-causes

2. Iwasaki Lab, Yale School of Medicine. Immunology of Long COVID. https://medicine.yale.edu/lab/iwasaki/projects/immunology-long-covid/

3. Talwar S, Harker JA, Openshaw PJM, Thwaites RS. Autoimmunity in long COVID. J Allergy Clin Immunol. 2025;155(4):1082–1094. doi:10.1016/j.jaci.2025.02.005. https://www.jacionline.org/article/S0091-6749(25)00171-X/fulltext

4. Autoimmune Association / Autoimmune Institute. Long COVID follows a pattern of post-viral illness. https://www.autoimmuneinstitute.org/covid_timeline/long-covid-follows-a-pattern-of-post-viral-illness/

5. Iwasaki A. What Have We Learned About Long COVID? Yale Insights / Health & Veritas podcast, 2025. https://insights.som.yale.edu/podcasts/health-veritas/akiko-iwasaki-what-have-we-learned-about-long-covid

6. Systematic review: Autoantibodies in long COVID. Lancet Infect Dis. 2025. (44 studies; 7,571 participants). https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00411-6/abstract

7. Backman I. New Evidence Supports Autoimmunity as One of Long COVID’s Underlying Drivers. Yale School of Medicine News, July 22, 2024. https://medicine.yale.edu/news-article/new-evidence-supports-autoimmunity-as-one-of-long-covids-underlying-drivers/

8. Backman I. Antibodies From Long COVID Patients Provide Clues to Autoimmunity Hypothesis. Yale Medicine News, August 5, 2024. https://www.yalemedicine.org/news/antibodies-from-long-covid-patients-provide-clues-to-autoimmunity-hypothesis

9. Giunta S, Giuliani A, Sabbatinelli J, Olivieri F. A multidimensional immunological perspective on long COVID. Cytokine Growth Factor Rev. 2025;84:1–11. doi:10.1016/j.cytogfr.2025.07.001. https://www.sciencedirect.com/science/article/abs/pii/S1568997225001429

10. Altmann DM, Whettlock EM, Liu S, Arachchillage DJ, Boyton RJ. The immunology of long COVID. Nat Rev Immunol. 2023;23(10):618–634. doi:10.1038/s41577-023-00904-7. https://www.nature.com/articles/s41577-023-00904-7

11. Iwasaki A (interview). AMA Update: What causes long COVID, brain fog, and the Yale Paxlovid study. American Medical Association, April 26, 2024. https://www.ama-assn.org/delivering-care/public-health/akiko-iwasaki-what-causes-long-covid-brain-fog-yale-paxlovid-study

12. Risk of new onset of immune-mediated diseases after SARS-CoV-2 infection: A systematic review and meta-analysis. Autoimmun Rev / Clin Immunol. 2025. https://www.sciencedirect.com/science/article/pii/S0049017225001763

13. Tzang CC, Sheng H, Kuo VF, et al. Association between COVID-19 and New-Onset Autoimmune Diseases: Updated Systematic Review and Meta-Analysis of 97 Million Individuals. Clin Rev Allergy Immunol. 2025;68(1):111. doi:10.1007/s12016-025-09124-4. https://pubmed.ncbi.nlm.nih.gov/41452424/

14. Wuller S, Singer NG, et al. Severity of acute SARS-CoV-2 infection and risk of new-onset autoimmune disease: A RECOVER initiative study in nationwide U.S. cohorts. PLoS One. 2025;20(6):e0324513. doi:10.1371/journal.pone.0324513. https://pmc.ncbi.nlm.nih.gov/articles/PMC12136303/

15. Hileman CO, Malakooti SK, Patil N, Singer NG, McComsey GA. New-onset autoimmune disease after COVID-19. Front Immunol. 2024;15:1337406. doi:10.3389/fimmu.2024.1337406. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1337406/full

16. Stein E, Heindrich C, Wittke K, et al. Efficacy of repeated immunoadsorption in patients with post-COVID myalgic encephalomyelitis/chronic fatigue syndrome and elevated β2-adrenergic receptor autoantibodies: a prospective cohort study. Lancet Reg Health Eur. 2024;49:101161. https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(24)00263-7/fulltext

17. Centers for Disease Control and Prevention. Long COVID: Signs, Symptoms, and Conditions. https://www.cdc.gov/long-covid/signs-symptoms/index.html

18. Mayo Clinic. COVID-19: Long-term effects. https://www.mayoclinic.org/diseases-conditions/coronavirus/in-depth/coronavirus-long-term-effects/art-20490351